AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
← catalyst calendarNCT05850234 · readout in 408 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
232estimated
Sites
36
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-07-20 | actual | When the study began enrolling |
| Primary completion | 2027-10-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-01-25 | estimated | The whole study's end, after follow-up |
| First posted | 2023-05-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsed/Refractory Multiple Myeloma
Intervention
- Biological: AZD0120
Primary outcomes
what the primary-completion date above is the date OFPhase 1b: Adverse Events (AEs)
measured Through study completion, a minimum of 2 years.
Phase 1b: Dose-Limiting Toxicities (DLTs)
measured 28 days
Phase 2: Objective Response Rate (ORR)
measured Through study completion, a minimum of 2 years.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed